Nothing Special   »   [go: up one dir, main page]

NO20002001L - Peptides capable of inhibiting the interaction between presenilines and the <beta> -amyloid peptide or its precursor - Google Patents

Peptides capable of inhibiting the interaction between presenilines and the <beta> -amyloid peptide or its precursor

Info

Publication number
NO20002001L
NO20002001L NO20002001A NO20002001A NO20002001L NO 20002001 L NO20002001 L NO 20002001L NO 20002001 A NO20002001 A NO 20002001A NO 20002001 A NO20002001 A NO 20002001A NO 20002001 L NO20002001 L NO 20002001L
Authority
NO
Norway
Prior art keywords
interaction
inhibiting
amyloid peptide
precursor
presenilines
Prior art date
Application number
NO20002001A
Other languages
Norwegian (no)
Other versions
NO328908B1 (en
NO20002001D0 (en
Inventor
Christian Czech
Luc Mercken
Laurent Pradier
Soline Reboul-Becquart
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9713384A external-priority patent/FR2770217B1/en
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20002001L publication Critical patent/NO20002001L/en
Publication of NO20002001D0 publication Critical patent/NO20002001D0/en
Publication of NO328908B1 publication Critical patent/NO328908B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)

Abstract

Nye polypeptider i stand til i det minste delvis å inhibere interaksjonen mellom presenilin 1 eller presenilin 2 på den ene side og forløperen av P-amyloidpeptid og/eller P-amyloidpeptid på den annen side.Videre beskrives in vitro-tester for påvisning av molekyler og særlig små molekyler i stand til å inhibere interaksjonen.Oppfinnelsens anvendelse på det farmasøytiske området beskrives.Novel polypeptides capable of at least partially inhibiting the interaction between presenilin 1 or presenilin 2 on the one hand and the precursor of β-amyloid peptide and / or β-amyloid peptide on the other hand. particularly small molecules capable of inhibiting the interaction. The application of the invention in the pharmaceutical field is described.

NO20002001A 1997-10-24 2000-04-17 In vitro use of a polypeptide capable of inhibiting the interaction between presenilines and APP. NO328908B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9713384A FR2770217B1 (en) 1997-10-24 1997-10-24 PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE PRECURSOR OF B-AMYLOID PEPTIDE AND / OR B-AMYLOID PEPTIDE
US9567198P 1998-08-07 1998-08-07
PCT/FR1998/002278 WO1999021886A1 (en) 1997-10-24 1998-10-23 PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE β-AMYLOID PEPTIDE OR ITS PRECURSOR

Publications (3)

Publication Number Publication Date
NO20002001L true NO20002001L (en) 2000-04-17
NO20002001D0 NO20002001D0 (en) 2000-04-17
NO328908B1 NO328908B1 (en) 2010-06-14

Family

ID=26233891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002001A NO328908B1 (en) 1997-10-24 2000-04-17 In vitro use of a polypeptide capable of inhibiting the interaction between presenilines and APP.

Country Status (13)

Country Link
EP (1) EP1025121B1 (en)
JP (1) JP2001521043A (en)
KR (1) KR100626475B1 (en)
CN (1) CN100429230C (en)
AU (1) AU766522B2 (en)
BR (1) BR9813105A (en)
CA (1) CA2305816C (en)
CY (1) CY1112236T1 (en)
CZ (1) CZ303226B6 (en)
HU (1) HU227660B1 (en)
IL (2) IL135751A0 (en)
NO (1) NO328908B1 (en)
WO (1) WO1999021886A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303226B6 (en) * 1997-10-24 2012-06-06 Aventis Pharma S. A. Process for detecting or isolating compounds intended for treatment of Alzheimer's disease
DE19909357A1 (en) * 1999-03-03 2000-09-07 Gerd Multhaup Copper agonist that binds to the APP copper binding site and / or has an inhibitory effect on the release of the amyloid-Aß peptide
WO2001062787A1 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis and treatment of bipolar affective disorder
WO2002074804A2 (en) * 2001-03-16 2002-09-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of binding domains of presenilins and transmembrane proteins for drug screening
US20080045499A1 (en) * 2006-02-06 2008-02-21 Elan Pharmaceuticals, Inc. Preferential Inhibition of Presenilin-1
US8129334B2 (en) * 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
JP2009532674A (en) * 2006-03-31 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and for improving normal memory
ES2530141B1 (en) * 2013-08-26 2016-01-15 Juan Carlos GALLAR RUIZ Peptide useful as a pharmacological target for the screening of molecules for the treatment and / or prevention of Alzheimer's disease, antibody against it and use of the antibody for the treatment and / or prevention of said disease.
CN108860921B (en) 2018-08-08 2020-11-20 上海鸿研物流技术有限公司 Collapsible container

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013069A1 (en) * 1991-01-21 1992-08-06 Imperial College Of Science, Technology & Medicine Test and model for alzheimer's disease
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
EP0876483A1 (en) * 1996-01-26 1998-11-11 HSC Research and Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
CZ303226B6 (en) * 1997-10-24 2012-06-06 Aventis Pharma S. A. Process for detecting or isolating compounds intended for treatment of Alzheimer's disease

Also Published As

Publication number Publication date
CY1112236T1 (en) 2015-12-09
EP1025121A1 (en) 2000-08-09
CZ20001462A3 (en) 2000-10-11
CN100429230C (en) 2008-10-29
WO1999021886A1 (en) 1999-05-06
AU766522B2 (en) 2003-10-16
BR9813105A (en) 2000-08-15
CN1277616A (en) 2000-12-20
IL135751A (en) 2010-12-30
HU227660B1 (en) 2011-10-28
IL135751A0 (en) 2001-05-20
NO328908B1 (en) 2010-06-14
KR100626475B1 (en) 2006-09-20
JP2001521043A (en) 2001-11-06
CA2305816C (en) 2012-07-10
CA2305816A1 (en) 1999-05-06
NO20002001D0 (en) 2000-04-17
EP1025121B1 (en) 2011-08-24
HUP0004605A3 (en) 2002-09-30
HUP0004605A1 (en) 2001-04-28
KR20010024541A (en) 2001-03-26
AU3129500A (en) 2000-12-14
CZ303226B6 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
DE69006306D1 (en) SYNTHETIC PEPTIDES OF THE CONJUGATE OF UBIQUITIN AND HISTONE H2A.
AU2672900A (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
CA2120358A1 (en) Hormone analogs with multiple ctp extensions
CA2270289A1 (en) Proteins with enhanced levels of essential amino acids
EP2295453A3 (en) An appetite-suppressing peptide, its compositions and use
DE69427370D1 (en) NEW INTEGRIN-BINDING PEPTIDES
RS50101B (en) Pharmaceutical compositions for immunomodulation
ATE280826T1 (en) CC CHEMOKINCEPTOR C-C CKR-5, DERIVATIVES THEREOF AND USES
BR9504791B1 (en) polypeptide compound and pharmaceutical composition.
ES2176284T3 (en) AMIDAS OF INHIBITING PEPTIDES OF THE CANCER OF HUMAN BEINGS.
CA2158058A1 (en) Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
DE69417252D1 (en) IMPROVED IMMUNOGENIC COMPOSITION AGAINST HUMAN GASTRIN 17
DE69938782D1 (en) PEPTIDES AS ANTIANGIOGENIC MEDICINAL PRODUCTS
NO972620D0 (en) RANTES peptide and fragments and mixtures comprising it for the treatment of inflammation
NO20002001L (en) Peptides capable of inhibiting the interaction between presenilines and the &lt;beta&gt; -amyloid peptide or its precursor
DE69533704D1 (en) BRADYKININ ANTAGONIST PEPTIDE WITH N-SUBSTITUTED GLYCINES
ATE397062T1 (en) CHIMERIC POLYPEPTIDES CONTAINING SHIGATOXIN FRAGMENT B AND PEPTIDES OF THERAPEUTIC INTEREST
NO972849D0 (en) Peptide p277 analogs and pharmaceutical compositions comprising these for the treatment or diagnosis of diabetes
BR9306272A (en) Peptide and pharmaceutical composition
CA2247328A1 (en) Neuropeptides originating in scorpion
EP1251176A3 (en) Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
DE69427363D1 (en) Platelet-inhibiting peptides
DK0833919T3 (en) Type F botulinum toxin and its use
NZ335136A (en) Isolated peptides which complex with hla-cw*16 molecules, and uses thereof

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees